Clinical Trials | November 14, 2025
Roche reports breakthrough phase III results for investigational multiple sclerosis drug
Fenebrutinib targets cells in the immune system known as B cells and microglia
Fenebrutinib targets cells in the immune system known as B cells and microglia
Nearly 1 in 3 HbA1c test results fall within the diabetic range, while 1 in 4 individuals show signs of prediabetes
FIBROSARC did not meet its primary PFS endpoint in the final analysi
This partnership has led to a 10% boost in delivery speed
Patients on baxdrostat showed a significant reduction in systolic blood pressure (SBP) compared to placebo
New funding to advance non-surgical brain interface technology and expand clinical and engineering capabilities globally
Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans
The partnership aligns with the launch of Oracle Health’s next-generation electronic health record
The results demonstrated meaningful reductions in the severity of involuntary movements and notable improvements in patient-reported quality of life
Enabling a new era in minimally invasive obesity treatment across Europe
Subscribe To Our Newsletter & Stay Updated
